Beugnet Frederic, Liebenberg Julian, Halos Lenaïg
Merial S.A.S., 29 Av Tony Garnier, 69007 Lyon, France.
ClinVet, Bloemfontein, South Africa.
Vet Parasitol. 2015 Jan 30;207(3-4):297-301. doi: 10.1016/j.vetpar.2014.12.007. Epub 2014 Dec 19.
A study was designed to compare the efficacy of NexGard(®) and Bravecto™, 2 recently introduced oral ectoparasiticides containing isoxazolines, against fleas (Ctenocephalides felis) on dogs. Twenty-four healthy dogs, weighing 9.2 kg to 28.6 kg, were included in this parallel group design, randomized, and controlled efficacy study. On Day -1, the 24 dogs were allocated to 3 study groups: untreated control; Nexgard(®) treated and Bravecto™ treated. The treatments were administered on Days 0, 28 and 56 for Nexgard(®) (labelled for monthly administration), and once on Day 0 for Bravecto™ (labelled for a 12 week use). Flea infestations were performed weekly with 100 adult unfed C. felis on each dog from Days 42 to 84. Fleas were counted and re-applied at 6 and 12 h post-infestation and removed and counted 24 h post-infestation. The arithmetic mean flea count for the untreated group ranged from 62.9 to 77.6 at 24 h post-infestation, indicating vigorous flea challenges on all assessment days. Both the Nexgard(®) and Bravecto™ treated groups had statistically significantly (p<0.05) less fleas compared to the untreated group on all assessment time points and days. Significantly fewer fleas were recorded for NexGard(®) treated dogs compared to Bravecto™ treated dogs at 6 h post-infestation on Day 56, 63, 70, 77 and 84 and at 12 h post-infestation on Days 70 and 84. No statistically significant (p<0.05) differences were recorded between the treated groups at 24 h post-infestation. Efficacies recorded 6 h post-infestation for Nexgard(®) ranged from 62.8% (Day 49) to 97.3% (Day 56), and efficacies ranged from 94.1% (Day 49) to 100% (Days 42, 56, 70 and 84) at 12 h post-infestation. Efficacies recorded for Bravecto™ ranged from 45.1% (Day 84) to 97.8% (Day 42) at 6 h post-infestation, and from 64.7% (Day 84) to 100% (Days 42 and 56) at 12 h post-infestation. Efficacies observed at 24 h were 100% for both products during the study except 99.6% on Day 84 for Bravecto™.
一项研究旨在比较NexGard（®）和Bravecto™这两种最近推出的含异恶唑啉的口服抗外寄生虫药对犬身上跳蚤（猫栉首蚤）的疗效。这项平行组设计、随机且对照的疗效研究纳入了24只体重在9.2千克至28.6千克之间的健康犬。在第-1天，将这24只犬分配到3个研究组：未治疗对照组；NexGard（®）治疗组和Bravecto™治疗组。NexGard（®）（标签标明每月给药一次）在第0、28和56天给药，Bravecto™（标签标明使用12周）在第0天给药一次。从第42天至84天，每周对每只犬用100只未进食的成年猫栉首蚤进行跳蚤感染。在感染后6小时和12小时对跳蚤进行计数并重新施加，在感染后24小时将跳蚤移除并计数。未治疗组在感染后24小时的算术平均跳蚤计数在62.9至77.6之间，表明在所有评估日都有强烈的跳蚤挑战。在所有评估时间点和天数，NexGard（®）治疗组和Bravecto™治疗组的跳蚤数量与未治疗组相比均有统计学显著差异（p<0.05）。在第56、63、70、77和84天感染后6小时以及第70和84天感染后12小时，NexGard（®）治疗的犬记录到的跳蚤数量明显少于Bravecto™治疗的犬。在感染后24小时，治疗组之间未记录到统计学显著差异（p<0.05）。NexGard（®）在感染后6小时的疗效范围为62.8%（第49天）至97.3%（第56天），在感染后12小时的疗效范围为94.1%（第49天）至100%（第42、56、70和84天）。Bravecto™在感染后6小时的疗效范围为45.1%（第84天）至97.8%（第42天），在感染后12小时的疗效范围为64.7%（第84天）至100%（第42和56天）。在研究期间，两种产品在感染后24小时观察到的疗效均为100%，除了Bravecto™在第84天为99.6%。
